Redeye believes Genovis to be excellently positioned to benefit both top-down and bottom-up in a scenario where the world economy and society potentially begin to see light at the end of the tunnel. Indeed, should the imminent global vaccine campaign turn out to be successful and things gradually return to some form of normal state of affairs during the second half of the year, we expect Genovis to significantly outperform in 2021. We have made no estimates changes.